Cramer's 'Buy the Dip' Call on Johnson & Johnson Fails to Account for Strong Recent Performance

Financial news analyst Jim Cramer recently encouraged investors to 'buy the dip' on Johnson & Johnson (JNJ), citing the company's upcoming data release at the Psych Congress conference. However, a closer look at JNJ's recent performance reveals that its 53.76% year-over-year growth and 31.99% year-to-date increase may not be typical of a defensive play.

Cramer highlighted JNJ's Caplyta and Spravato treatments, but the company had already published data on these assets hours before his segment aired. Furthermore, JNJ's recent quarterly sales report showed operational growth of 5.6%, with oncology leading the way. The company also raised its 2026 outlook to reported sales of $101.1 billion and reported EPS of $11.60 to $11.75.

Investors should be cautious when evaluating Cramer's dip call, as JNJ has been outperforming the broader market. With upcoming catalysts including the Icotide readout in psoriatic arthritis and the Enterprise Business Review scheduled for December 8, investors would do well to carefully consider their options.